Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2024

Open Access 01-12-2024 | Dolutegravir | Research

Efficacy, safety, and tolerability of dolutegravir-based ART regimen in Durban, South Africa: a cohort study

Authors: Nivriti Hurbans, Panjasaram Naidoo

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Background

Dolutegravir is an integrase strand transfer inhibitor that has been recommended for use in first-line antiretroviral regimens by the World Health Organisation and is currently being rolled out globally. There has been safety concerns with dolutegravir which has caused concern about its use in the general population. Dolutegravir first-line regimens have been used in South Africa since early 2020. Therefore, the aim of the present study was to assess the efficacy, safety, and tolerability of first-line dolutegravir-based antiretrovirals amongst adults living with HIV in Durban, South Africa.

Methods

This was a mixed-methods study, which comprised a cross-sectional survey and longitudinal retrospective follow-up of medical records. The study was conducted between October 2020 and January 2022. Data were described using descriptive and summary statistics. Bivariate logistic regression was applied to socio-demographic and clinical variables and crude odds ratios with a 95% confidence interval was calculated. Pearson chi-square tests, paired sample T-tests, and cross-tabulations were performed on selected variables.

Results

A total of 461 participants were enrolled in the study. There was a significant change in immunological outcomes (p < 0.001) after dolutegravir initiation. Furthermore, an assessment of laboratory parameters showed that there was a significant decrease in cholesterol (p < 0.001) and increase in creatinine (p < 0.001) levels. Increased weight was shown by 60.7% of the participants but was not associated with age, gender, CD4 counts, and previous antiretroviral usage. The study found that 43.6% of the participants experienced at least one side-effect. A total of 21.6% and 23.2% of the participants experienced neuropsychiatric and central nervous system side-effects, respectively. In the bivariate analyses, only gender was shown to be associated with side-effects, and only 1.7% of the participants discontinued the study due to side-effects.

Conclusion

Our results suggest that dolutegravir is effective, safe, and well tolerated in the study population.
Literature
1.
Dow DE, Bartlett JA. Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV. Infect Dis Therapy. 2014;3(2):83–102.CrossRef
2.
Podany AT, Scarsi KK, Fletcher CV. Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors. Clin Pharmacokinet. 2017;56(1):25–40.CrossRefPubMedPubMedCentral
3.
Hill A, Waters L, Pozniak A. Are new antiretroviral treatments increasing the risks of clinical obesity? J Virus Eradication. 2019;5(1):41–3.CrossRef
4.
Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter F, et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? AIDS. 2018;32(12):1551–61.CrossRefPubMed
5.
Chimukangara B, Lessells RJ, Rhee S-Y, Giandhari J, Kharsany AB, Naidoo K, et al. Trends in pretreatment HIV-1 drug resistance in antiretroviral ipy-naive adults in South Africa, 2000–2016: a pooled sequence analysis. EClinicalMedicine. 2019;9:26–34.CrossRefPubMedPubMedCentral
6.
World Health Organisation. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. 2016.
7.
World Health Organisation. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organisation; 2018.
8.
World Health Organisation. HIV Drug Resistance Report 2019. 2019.
9.
Castellino S, Moss L, Wagner D, Borland J, Song I, Chen S, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother. 2013;57(8):3536–46.CrossRefPubMedPubMedCentral
10.
Blanco JL, Whitlock G, Milinkovic A, Moyle G. HIV integrase inhibitors: a new era in the treatment of HIV. Expert Opin Pharmacother. 2015;16(9):1313–24.CrossRefPubMed
11.
Dorward J, Lessells R, Drain PK, Naidoo K, de Oliveira T, Pillay Y, et al. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. Lancet HIV. 2018;5(7):e400–4.CrossRefPubMedPubMedCentral
12.
Derache A, Iwuji CC, Danaviah S, Giandhari J, Marcelin A-G, Calvez V, et al. Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART. J Antimicrob Chemother. 2019;74(2):473–9.CrossRefPubMed
13.
Murphy RA, Court R, Maartens G, Sunpath H. Second-line antiretroviral therapy in sub-saharan Africa: it is time to mind the gaps. AIDS Res Hum Retroviruses. 2017;33(12):1181–4.CrossRefPubMedPubMedCentral
14.
SA Department of Health. 2019 ART Clinical Guidelines for the Management of HIV in Adults, Pregnancy, Adolescents, Children, Infants and Neonates. NDoH Pretoria. 2019.
15.
de Boer MG, van den Berk GE, van Holten N, Oryszcyn JE, Dorama W, Brinkman K. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS. 2016;30(18):2831–4.CrossRefPubMed
16.
Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56–63.CrossRefPubMed
17.
Moss JA. HIV/AIDS Rev Radiologic Technol. 2013;84(3):247–67.
18.
Venter W, Kaiser B, Pillay Y, Conradie F, Gomez G, Clayden P, et al. Cutting the cost of South African antiretroviral therapy using newer, safer drugs. South Afr Med J. 2017;107(1):28–30.CrossRef
19.
Meyer-Rath G, Johnson LF, Pillay Y, Blecher M, Brennan AT, Long L, et al. Changing the South African national antiretroviral therapy guidelines: the role of cost modelling. PLoS ONE. 2017;12(10):e0186557.CrossRefPubMedPubMedCentral
20.
World Health Organisation. Policy brief: Update of recommendations on first-and second‐line antiretroviral regimens. 2019.
21.
World Health Organisation. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. World Health Organization; 2021.
22.
Rutstein SE, Hosseinipour MC, Weinberger M, Wheeler SB, Biddle AK, Wallis CL, et al. Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm. BMC Infect Dis. 2016;16:1–13.CrossRef
23.
Abdissa A, Yilma D, Fonager J, Audelin AM, Christensen LH, Olsen MF, et al. Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia. BMC Infect Dis. 2014;14:1–7.CrossRef
24.
Moosa A, Gengiah TN, Lewis L, Naidoo K. Long-term adherence to antiretroviral therapy in a South African adult patient cohort: a retrospective study. BMC Infect Dis. 2019;19(1):1–12.CrossRef
25.
Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013;52(11):981–94.CrossRefPubMedPubMedCentral
26.
Bhatti AB, Usman M, Kandi V. Current scenario of HIV/AIDS, treatment options, and major challenges with compliance to antiretroviral therapy. Cureus. 2016;8(3).
27.
Hongo H, Nagao T, Nakamura K, Kitaichi T, Maeno Y, Tokunaga T, et al. Safety and effectiveness analysis of dolutegravir in patients with HIV-1: interim report of post-marketing surveillance in Japan. Adv Therapy. 2021;38(8):4480–504.CrossRef
28.
Elzi L, Erb S, Furrer H, Cavassini M, Calmy A, Vernazza P, et al. Adverse events of raltegravir and dolutegravir. AIDS. 2017;31(13):1853.CrossRefPubMed
29.
Curtis L, Nichols G, Stainsby C, Lim J, Aylott A, Wynne B, et al. Dolutegravir: clinical and laboratory safety in integrase inhibitor–naive patients. HIV Clin Trial. 2014;15(5):199–208.CrossRef
30.
Park TE, Mohamed A, Kalabalik J, Sharma R. Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Expert Rev Anti-infective Therapy. 2015;13(10):1195–212.CrossRefPubMed
31.
Peñafiel J, de Lazzari E, Padilla M, Rojas J, Gonzalez-Cordon A, Blanco JL, et al. Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother. 2017;72(6):1752–9.CrossRefPubMed
32.
World Health Organisation. Update of recommendations on first-and second-line antiretroviral regimens. World Health Organization Geneva; 2019.
33.
Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, et al. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-saharan Africa: a modelling study. Lancet HIV. 2019;6(2):e116–27.CrossRefPubMed
34.
35.
Yuh B, Tate J, Butt AA, Crothers K, Freiberg M, Leaf D, et al. Weight change after antiretroviral therapy and mortality. Clin Infect Dis. 2015;60(12):1852–9.CrossRefPubMedPubMedCentral
36.
Koethe JR, Lukusa A, Giganti MJ, Chi BH, Nyirenda CK, Limbada MI et al. Association between weight gain and clinical outcomes among malnourished adults initiating antiretroviral therapy in Lusaka, Zambia. Journal of Acquired Immune Deficiency Syndromes (1999). 2010;53(4):507.
37.
Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis. 2020;70(4):549–56.PubMed
38.
Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, et al. Weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527.CrossRefPubMedPubMedCentral
39.
Menard A, Meddeb L, Tissot-Dupont H, Ravaux I, Dhiver C, Mokhtari S, et al. Dolutegravir and weight gain: an unexpected bothering side effect? AIDS. 2017;31(10):1499–500.CrossRefPubMed
40.
Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379–89.CrossRefPubMed
41.
Romo ML. The Global Implementation of Dolutegravir for HIV Treatment. 2022.
42.
Patel DA, Snedecor SJ, Tang WY, Sudharshan L, Lim JW, Cuffe R et al. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1–infected patients: a systematic review and network meta-analysis. PLoS ONE. 2014;9(9).
43.
Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig. 2015;35:211–9.CrossRefPubMedPubMedCentral
44.
Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41(2):353–61.CrossRefPubMed
45.
Gutierrez F, Fulladosa X, Barril G, Domingo P. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Rev. 2014;16(4):199–212.PubMed
46.
Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, et al. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–18.CrossRefPubMed
47.
Keeshin SW, Feinberg J. Evaluation of dolutegravir safety for the treatment of HIV-1. Exp Opin Drug Saf. 2015;14(1):141–7.CrossRef
48.
DeAnda F, Hightower KE, Nolte RT, Hattori K, Yoshinaga T, Kawasuji T, et al. Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics. PLoS ONE. 2013;8(10):e77448.CrossRefPubMedPubMedCentral
Metadata
Title
Efficacy, safety, and tolerability of dolutegravir-based ART regimen in Durban, South Africa: a cohort study
Authors
Nivriti Hurbans
Panjasaram Naidoo
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-024-09202-6

Other articles of this Issue 1/2024

BMC Infectious Diseases 1/2024 Go to the issue

Case Report

Clinical presentation and treatment of 2 patients with infection caused by Chromobacterium violaceum in Vietnam

Research

Predictors of quality of life of TB/HIV co-infected patients in the Northern region of Ghana

Research

Identification of associated risk factors for serological distribution of hepatitis B virus via machine learning models

Research

Tuberculosis treatment delay and associated factors among pulmonary tuberculosis patients at public health facilities in Dale District and Yirgalem Town administration, Sidama Region, South Ethiopia

Research

A systematic review and meta-analysis of circulating serum and plasma microRNAs in TB diagnosis

Research

Prognostic impacts of repeated sepsis in intensive care unit on autoimmune disease patients: a retrospective cohort study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits